Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

甲型流感病毒（IAV）仍然是一个全球性的健康问题，尽管每年的疫苗接种工作。临床干预 能够预防与严重IAV感染相关的免疫病理学和“细胞因子风暴”， 需要，特别是可以在感染后期启动的方法。知识来自于 拟议的研究将促进开发基于IL-2的治疗方法的新应用， 治疗严重的呼吸道病毒感染，以及推进其作为佐剂的潜在用途， 接种疫苗后的IAV特异性免疫。

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.